TORONTO, ON--(Marketwired - April 18, 2017) - MaRS Innovation (MI) and its South Korean partner, Korea Health Industry Development Institute (KHIDI), continue to build on the five-year global partnership agreement signed in December 2016 during Premier Wynne's mission to the Republic of Korea.
Together with Minister Moridi, Ontario Minister of Research, Innovation and Science, Rafi Hofstein, CEO of MI, is in Seoul to further the joint research initiatives first envisaged last year. Five outstanding Ontario scientists from some of MI's Member institutions are ...
TORONTO (February 13, 2017): QD Solar, a Canadian technology company created by MaRS Innovation and the University of Toronto, announced today the closing of a C$2.5M Series A funding led by DSM Venturing, with matching investment participation from existing investors, MaRS innovation and KAUST Innovation Fund.
The development of this technology is also supported by project funding that was announced in March 2016 from Sustainable Development Technology Canada (SDTC) through a C$2.5M grant, and through the generous support of the Ontario Research ...
New paper published in The Lancet Diabetes & Endocrinology recommends exercise guidelines for type 1 diabetes patients and healthcare providers.
Experts from JDRF, the leading global organization focused on type 1 diabetes (T1D) research, as part of an international team of 21 researchers and clinicians led by York UniversityProfessor Michael Riddell, published first-of-its-kind guidelines to help people with type 1 diabetes exercise safely.
The report, “Exercise management in type 1 diabetes: a consensus statement,” published this week in The Lancet Diabetes & Endocrinology, offers guidelines on ...
XOR-Labs Toronto (XOR) a spin-oXOR-Labs Toronto (XOR) a spin-off from Toronto General Hospital at University Health Network today announced the closing of another financing through a private placement, led by lead investor Regenesis Limited Partnership, along with the participation of its existing investors, including Xenios AG and MaRS Innovation. The total raised in this round is CAN$2.85M. This is a solid vote of confidence and the second investment in XOR for Xenios which invested an additional CAN$2.6M in the company in ...
Toronto, August 18, 2016 – Toronto-based ScarX Therapeutics (ScarX) has received approval from Health Canada to begin a Phase I clinical trial of its SCX-001 nefopam cream, a first-of-its-kind topical treatment developed to significantly reduce surgical scarring.
This announcement was covered in Yahoo Finance, The Canadian Business Journal, Global News Wire, and BioSpace.
Applied immediately after surgical wound closure, SCX-001 reduces the amount of scar tissue that develops during the body’s natural healing process. The 24-subject Phase I clinical trial will be conducted at ...
UTEST graduate company building a versatile, smart, modular power bar
We've all been there: You reach over behind your TV to plug in yet another device to find your power bar’s out of available outlets. You wonder why your electricity bill’s so high and want to know which appliance is the culprit. You forget to turn something off (or did you?) and you’re already halfway to a meeting.
Knitt Labs, Inc. has developed KnittBar to solve these frustrating problems for those who are ...
TORONTO and SAN DIEGO (June 4, 2016) — Triphase Accelerator Corporation, a private drug development company dedicated to advancing novel compounds through Phase 2 proof-of-concept, today announced positive results from its Phase 1 proof-of-concept study evaluating marizomib in combination with bevacizumab in patients with WHO grade IV malignant glioma.
These results were presented in a poster session during the American Society for Clinical Oncology (ASCO) annual meeting in Chicago on June 4, 2016.
“These results confirm our original hypothesis that this combination therapy is ...
Biotechnology Focus, a compendium of the Canadian life sciences industry, has published the following guest column by Dr. Raphael Hofstein, MaRS Innovation’s president & CEO, and Elizabeth Monier-Williams, director of marketing and communications.
There’s a historical trend in Canadian culture with far-reaching effects for the way we do business, ranging from entertainment to academia to science. Namely, it’s that until quite recently, Canadians weren’t into cultivating national star systems. 
As Gideon Hayden recently wrote for TechCrunch, if you’re a Canadian tall poppy ...
The Journal of Clinical Chemistry recently hosted Dr. David Sinton of the University of Toronto in a podcast to highlight his work on commercializing technology for human sperm selection.
Shatha Qaqish, manager, Technology and Venture Development at MaRS Innovation, is working with Dr. Sinton to commercialize his off-the-shelf device for sperm count.
You can listen to the podcast here.
By Stephanie Meszaros, marketing and communications specialist.